The Efficacy of Nanoparticle Delivery to Hypoxic Solid Tumors by ciRGD Co‐Administration Depends on Neuropilin‐1 and Neutrophil Levels
Source abstract
Abstract
Abstract The ability to improve nanoparticle delivery to solid tumors is an actively studied domain, where various mechanisms are looked into. In previous work, the authors have looked into nanoparticle size, tumor vessel normalization, and disintegration, and here it is aimed to continue this work by performing an in‐depth mechanistic study on the use of ciRGD peptide co‐administration. Using a multiparametric approach, it is observed that ciRGD can improve nanoparticle delivery to the tumor itself, but also to tumor cells specifically better than vessel normalization strategies. The effect depends on the level of tumor perfusion, hypoxia, neutrophil levels, and vessel permeability. This work shows that upon characterizing tumors for these parameters, conditions can be selected that can optimally benefit from ciRGD co‐administration as a means to improve NP delivery to solid tumors.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · Extracellular vesicles in disease
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
NanoHealth and Optical Imaging Group Department of Imaging and Pathology KU Leuven Herestraat 49 Leuven B3000 Belgium
Atomic & Mass Spectrometry – A&MS research group Department of Chemistry Ghent University Campus Sterre, Krijgslaan 281‐S12 Ghent 9000 Belgium
Translational Cell and Tissue Research Unit Department of Imaging and Pathology KU Leuven Herestraat 49 Leuven B3000 Belgium
Leuven Cancer Research Institute Faculty of Medical Sciences KU Leuven Herestraat 49 Leuven B3000 Belgium
References (64)
Show source-provided references
1. 10.1016/j.ejpb.2015.03.01810.1016/j.ejpb.2015.03.018 ↗
2. 10.2217/nnm.16.510.2217/nnm.16.5 ↗
3. 10.1073/pnas.210925611810.1073/pnas.2109256118 ↗
4. 10.1016/j.addr.2018.07.00710.1016/j.addr.2018.07.007 ↗
5. 10.1038/natrevmats.2017.2410.1038/natrevmats.2017.24 ↗
6. 10.1021/acs.chemrev.0c0077910.1021/acs.chemrev.0c00779 ↗
7. 10.1021/acsnano.9b0392410.1021/acsnano.9b03924 ↗
8. 10.1038/natrevmats.2016.1410.1038/natrevmats.2016.14 ↗
9. 10.7150/ntno.2056410.7150/ntno.20564 ↗
10. 10.1186/s12951-022-01727-910.1186/s12951-022-01727-9 ↗
11. 10.1101/2023.04.2753855910.1101/2023.04.27538559 ↗
12. 10.1126/science.118305710.1126/science.1183057 ↗
13. 10.1172/JCI9228410.1172/JCI92284 ↗
14. 10.1007/s00262-013-1500-010.1007/s00262-013-1500-0 ↗
15. 10.1073/pnas.152126511310.1073/pnas.1521265113 ↗
16. 10.1038/s41563-019-0566-210.1038/s41563-019-0566-2 ↗
17. 10.1016/j.cmet.2019.06.00110.1016/j.cmet.2019.06.001 ↗
18. 10.1038/s41467-021-22801-010.1038/s41467-021-22801-0 ↗
19. 10.1158/2159-8290.CD-19-135310.1158/2159-8290.CD-19-1353 ↗
20. 10.1016/j.cell.2017.01.01810.1016/j.cell.2017.01.018 ↗
21. 10.1016/j.ccell.2016.10.00610.1016/j.ccell.2016.10.006 ↗
22. 10.1007/s10456-017-9573-610.1007/s10456-017-9573-6 ↗
23. 10.1038/nrd345510.1038/nrd3455 ↗
24. 10.1016/j.ccell.2014.10.00610.1016/j.ccell.2014.10.006 ↗
25. 10.1038/nnano.2012.4510.1038/nnano.2012.45 ↗
26. 10.3389/fonc.2019.0122710.3389/fonc.2019.01227 ↗
27. 10.3390/nano1204068210.3390/nano12040682 ↗
28. 10.1021/acsnano.9b0814210.1021/acsnano.9b08142 ↗
29. 10.1016/j.nantod.2016.04.00810.1016/j.nantod.2016.04.008 ↗
30. 10.1073/pnas.211245711810.1073/pnas.2112457118 ↗
31. 10.1096/fj.00-0250com10.1096/fj.00-0250com ↗
32. 10.1016/j.jconrel.2015.01.01110.1016/j.jconrel.2015.01.011 ↗
33. 10.1016/j.ccr.2013.11.00710.1016/j.ccr.2013.11.007 ↗
34. 10.1007/s10456-020-09715-z10.1007/s10456-020-09715-z ↗
35. 10.1021/acsnano.7b0721410.1021/acsnano.7b07214 ↗
36. 10.3390/cancers1317444410.3390/cancers13174444 ↗
37. 10.1593/neo.0955410.1593/neo.09554 ↗
38. 10.1021/acsnano.5b0202810.1021/acsnano.5b02028 ↗
39. 10.1136/gutjnl-2012-30252910.1136/gutjnl-2012-302529 ↗
40. 10.1016/j.jconrel.2016.11.01510.1016/j.jconrel.2016.11.015 ↗
41. 10.1021/acs.bioconjchem.6b0043710.1021/acs.bioconjchem.6b00437 ↗
42. 10.1021/acsnano.1c0451010.1021/acsnano.1c04510 ↗
43. 10.1038/nnano.2016.16810.1038/nnano.2016.168 ↗
44. 10.1096/fj.201601238R10.1096/fj.201601238R ↗
45. 10.1152/ajplung.00149.202010.1152/ajplung.00149.2020 ↗
46. 10.1002/mc.2293610.1002/mc.22936 ↗
47. 10.1016/j.ctro.2019.09.00610.1016/j.ctro.2019.09.006 ↗
48. 10.1016/j.ccell.2020.03.00710.1016/j.ccell.2020.03.007 ↗
49. 10.1038/s41419-021-03682-z10.1038/s41419-021-03682-z ↗
50. 10.1111/j.1365-2613.2009.00641.x10.1111/j.1365-2613.2009.00641.x ↗
51. 10.3390/cancers1403053610.3390/cancers14030536 ↗
52. 10.1016/S1074-5521(96)90178-710.1016/S1074-5521(96)90178-7 ↗
53. 10.1038/nrc109310.1038/nrc1093 ↗
54. 10.1111/micc.1212410.1111/micc.12124 ↗
55. 10.1161/ATVBAHA.118.31111810.1161/ATVBAHA.118.311118 ↗
56. 10.1038/s41467-021-27263-y10.1038/s41467-021-27263-y ↗
57. 10.1074/jbc.M116.77305110.1074/jbc.M116.773051 ↗
58. 10.1182/blood.202101101010.1182/blood.2021011010 ↗
59. 10.3389/fimmu.2022.72615310.3389/fimmu.2022.726153 ↗
60. 10.3390/ijms2104118310.3390/ijms21041183 ↗
61. 10.3390/jpm1102012410.3390/jpm11020124 ↗
62. 10.7554/eLife.1758410.7554/eLife.17584 ↗
63. 10.20892/j.issn.2095-3941.2020.006910.20892/j.issn.2095-3941.2020.0069 ↗
64. 10.1038/s41467-020-16596-910.1038/s41467-020-16596-9 ↗